Abstract P1-02-02: Examination of low Her2 expression in breast cancer
Aileen I. Fernandez(Yale University), David L. Rimm(Yale University), Rinda Soong(University of Pittsburgh Medical Center), Kimmie Rabe(University of Minnesota), Esther Yoon(Cleveland Clinic Florida), Lajos Pusztai(Yale University), Kamaljeet Singh, Julie M. Jorns(Medical College of Wisconsin), Krisztina Hanley(Emory University), Emily Reisenbichler(Saint Louis University), Oluwole Fadare(University of California, San Diego), Olivia L. Snir(Oregon Health & Science University), Andrew M. Bellizzi(University of Iowa), Malini Harigopal, Mirna Podoll(Breast Cancer Research Foundation), Hannah Y. Wen(Memorial Sloan Kettering Cancer Center), Mary Ann Sanders(University of Louisville), Jane B. Brock(Brigham and Women's Hospital), Matthew Liu(Yale University), Amy Ly(Washington University in St. Louis), Shi Wei(University of Alabama at Birmingham), Serena Wong(Yale University), M. Gabriela Kuba(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k